The mechanism whereby some tumor cells downregulate TFPI-2 synthesis has been primarily attributed to transcriptional silencing through hypermethylation of CpG sites in the TFPI-2 promoter [10-14], inasmuch as treatment of these tumor cells with a methyltransferase inhibitor, 5'-aza-2'-deoxycytidine, restored TFPI-2 transcription[14]. This evidence concerns the gene TFPI2 and neoplasm.